ClinicalTrials.gg
CompletedNCT01374802Updated Jul 31, 2015Results posted

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

A Phase 1 interventional study of Darunavir and Ritonavir in HIV Infections, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-31.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing darunavir in HIV Infections — 2 open to participants now, 3 under way, 2 of them phase 3. Darunavir · HIV Infections.

Enrollment
34th of 38
14 · median 90
Started
2011
with 2 others
Phase 1
3 of 38
none open now
Registered
28th of 38
by date
Lead sponsor
2 of 38
Boehringer Ingelheim

Among the 38 studies testing darunavir in HIV Infections, this one is the 34th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 1, and was the 28th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 38 studies testing darunavir in HIV Infections are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About darunavir

Darunavir: first FDA approval 2006 (PREZISTA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing darunavir in HIV Infections, or all of them as a file.
02

Study summary

The objective of the current study is to investigate the effect of multiple oral daily doses of BI 201335 on the steady-state pharmacokinetics of darunavir co-administered with ritonavir.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects according to the following criteria: medical history, physical examination, vital signs (blood pressure, pulse rate), 12-lead (ECG), clinical laboratory tests
  2. Age 18 to 55 years (incl.)
  3. (BMI) 18.5 to 29.9 kg/m2 (incl.) and weight greater than 50 kg
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation.

Exclusion criteria

Exclusion criteria:

  1. Any finding of the medical examination (including blood pressure (BP), pulse rate (PR) and ) deviating from normal and of clinical relevance
  2. Any evidence of a concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. History of photosensitivity or recurrent rash.
  5. Surgery of the gastrointestinal tract (except appendectomy)
  6. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  7. History of relevant orthostatic hypotension, fainting spells or blackouts.
  8. Chronic or relevant acute infections
  9. History of relevant allergy/ (including allergy to drug or its )
  10. Intake of drugs with a long half-life (more than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  11. Participation in another trial with an drug within two months prior to administration or during the trial
  12. Smoker (more than 10 cigarettes)
  13. Inability to refrain from smoking on trial days
  14. Alcohol abuse (more than 30 g/day)
  15. Drug abuse
  16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  17. outside the normal range or any other laboratory value outside the reference range that is of clinical relevance
  18. Inability to comply with dietary regimen of trial site
  19. The subject is not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
  20. Positive serology tests for (HIV) and / C virus
  21. Vulnerable subjects (e.g. persons kept in detention)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    BI 201335

    capsule for oral administration

    Drug: BI 201335

  • Experimental
    Darunavir 400 mg

    tablet for oral administration

    Drug: Darunavir

  • Experimental
    Ritonavir 100 mg

    tablet for oral administration

    Drug: Ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss of Darunavir

    area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

    Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)

  2. Cτ,ss of Darunavir

    concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir

    Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)

  3. Cmax,ss of Darunavir

    maximum measured concentration of the analyte in plasma at steady-state

    Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)

Secondary outcomes

  1. Tmax,ss of Darunavir

    time from last dosing to maximum concentration of the analyte in plasma at steady state

    Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)

07

Results

Posted Jul 31, 2015

Participant flow

Participant flow — Overall Study
MilestoneAll Subjects
Started14
Completed14
Not completed0

Outcome measures

PrimaryAUCτ,ss of Darunavir

area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

Time frame:
0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
Reported as:
Geometric mean · ng*h/mL
AUCτ,ss of Darunavir
ng*h/mLDarunavir+RitonavirFaldaprevir+Darunavir+Ritonavir
AUCτ,ss of Darunavir57200 ± 29.566000 ± 39.9
Statistical analysis
  • Darunavir+Ritonavir vs Faldaprevir+Darunavir+Ritonavir · ANOVA · Geometric mean ratio: 115.29 · 90% CI 101.36 to 131.13the standard deviation is actually the geometric coefficient of variation
PrimaryCτ,ss of Darunavir

concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir

Time frame:
0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
Reported as:
Geometric mean · ng/mL
Cτ,ss of Darunavir
ng/mLDarunavir+RitonavirFaldaprevir+Darunavir+Ritonavir
Cτ,ss of Darunavir1330 ± 49.51170 ± 90.3
Statistical analysis
  • Darunavir+Ritonavir vs Faldaprevir+Darunavir+Ritonavir · ANOVA · Geometric mean ratio: 87.91 · 90% CI 68.609 to 112.630the standard deviation is actually the geometric coefficient of variation
PrimaryCmax,ss of Darunavir

maximum measured concentration of the analyte in plasma at steady-state

Time frame:
0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
Reported as:
Geometric mean · ng/mL
Cmax,ss of Darunavir
ng/mLDarunavir+RitonavirFaldaprevir+Darunavir+Ritonavir
Cmax,ss of Darunavir4930 ± 23.96330 ± 26.5
Statistical analysis
  • Darunavir+Ritonavir vs Faldaprevir+Darunavir+Ritonavir · ANOVA · Geometric mean ratio: 128.41 · 90% CI 115.724 to 142.489the standard deviation is actually the geometric coefficient of variation
SecondaryTmax,ss of Darunavir

time from last dosing to maximum concentration of the analyte in plasma at steady state

Time frame:
0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
Reported as:
Median · h
Tmax,ss of Darunavir
hDarunavir+RitonavirFaldaprevir+Darunavir+Ritonavir
Tmax,ss of Darunavir1.50 ± 33.92.01 ± 37.3

Adverse events

Collected over Adverse events (AEs) occurring up to 9 days after first drug administration of DRV/r were assigned to the treatment DRV/r and AEs occurring up to 13 days after last drug administration of DRV/r+FDV were assigned to the combined treatment DRV/r+FDV.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Darunavir+Ritonavir—0/14 (0%)7/14 (50%)
Faldaprevir+Darunavir+Ritonavir—0/14 (0%)11/14 (78.6%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventDarunavir+RitonavirFaldaprevir+Darunavir+Ritonavir
DiarrhoeaGastrointestinal disorders1/146/14
Abdominal distensionGastrointestinal disorders0/144/14
HeadacheNervous system disorders2/143/14
FatigueGeneral disorders3/140/14
NauseaGastrointestinal disorders1/142/14
Decreased appetiteMetabolism and nutrition disorders0/141/14
InsomniaPsychiatric disorders0/141/14
NervousnessPsychiatric disorders0/141/14
Sleep disorderPsychiatric disorders1/140/14
DizzinessNervous system disorders1/140/14

Baseline characteristics

The study was performed as an open-label, multiple-dose, single-group, fixed-sequence study in 14 healthy volunteers.

Age, Continuous
Age, Continuous(years)All Subjects
Mean40.4 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female2
Male12
08

Study locations

1 site
  • 1220.49.1 Boehringer Ingelheim Investigational Site
    Berlin, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011 and a primary completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2011
First posted
Jun 16, 2011
Start
Jun 2011
Primary completionActual
Jul 2011
Results first posted
Jul 31, 2015
Last update
Jul 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01374802
Responsible party
Sponsor
First posted
Jun 16, 2011
Start date
Jun 2011
Primary completion
Jul 2011
Results posted
Jul 31, 2015
Last update
Jul 31, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darunavir · Ritonavir · Faldaprevir

Start the discussion